NCT02893917View on ClinicalTrials.gov

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

August 11, 2017

Primary Completion Date

March 14, 2023

Study Completion Date

June 18, 2026

Conditions
Advanced Prostate Adenocarcinoma With Neuroendocrine DifferentiationCastration-Resistant Prostate CarcinomaMetastatic Prostate Adenocarcinoma With Neuroendocrine DifferentiationMetastatic Prostate CarcinomaProstate Adenocarcinoma With Neuroendocrine DifferentiationStage IV Prostate Adenocarcinoma AJCC v7
Interventions
DRUG

Cediranib

Given PO

DRUG

Olaparib

Given PO

Trial Locations (16)

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

23298

VCU Massey Comprehensive Cancer Center, Richmond

33612

Moffitt Cancer Center, Tampa

37232

Vanderbilt University/Ingram Cancer Center, Nashville

43210

Ohio State University Comprehensive Cancer Center, Columbus

48201

Wayne State University/Karmanos Cancer Institute, Detroit

48334

Weisberg Cancer Treatment Center, Farmington Hills

92093

UC San Diego Moores Cancer Center, La Jolla

92103

UC San Diego Medical Center - Hillcrest, San Diego

95817

University of California Davis Comprehensive Cancer Center, Sacramento

06510

Smilow Cancer Center/Yale-New Haven Hospital, New Haven

06520

Yale University, New Haven

02114

Massachusetts General Hospital Cancer Center, Boston

02115

Brigham and Women's Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH